Lords Mark Industries has successfully completed its NCLT-approved reverse merger with Kratos Energy & Infrastructure, reporting a consolidated profit of Rs 48.59 crore for FY 2025-26. The entity now operates across healthcare, biotechnology, and renewables, with a newly reconstituted board and a focus on SEBI compliance.
Lords Mark Industries Reports Financial Results Post-Merger
Consolidated Revenue: Rs 684.75 Crore | Consolidated Profit After Tax (PAT): Rs 48.59 Crore
Reader Takeaway: Successful emergence from NCLT process drives profitability, though post-merger integration and new SEBI compliance mandates remain key watch areas.
What just happened
Lord’s Mark Industries Ltd has concluded a transformative fiscal year (2025-26) following its NCLT-approved resolution plan. The company executed a reverse merger with Kratos Energy & Infrastructure Limited, establishing itself as an integrated listed entity. The process involved comprehensive debt settlement, capital restructuring, and the appointment of an expanded board to oversee the next phase of operations.
Why this matters
The company has moved from insolvency proceedings to operational profitability. With an authorized capital of Rs 800 crore and a paid-up capital of Rs 426.62 crore, the entity is now positioned to focus on its core business verticals: healthcare, medical diagnostics, biotechnology, and renewable energy. The filing confirms that the company is aligning with SEBI (LODR) regulations for the upcoming 2026-27 fiscal year.
The backstory
Following the merger, the company has diversified its reach through initiatives like 'Lord’s Sehat' walk-in clinics and strategic partnerships within the MedTech space. The brand has sought to increase visibility by appointing cricket icon Rahul Dravid as the brand ambassador for its MedTech division. These moves signal an attempt to build a consumer-facing presence after years of restructuring.
Board and Governance Update
As part of its governance overhaul, the company reconstituted its board effective mid-2026. Four new Independent Directors—Shweta Dilip Mehta, Govind Singh Bhati, Vinod Tiwari, and Pooja Vijay Gohil—have joined the board. Additionally, the company has proposed M/s Sanjeev S Gupta & Associates as statutory auditors for a five-year tenure.
Risks to watch
Investors should monitor the integration risks associated with merging multiple entities, particularly in supply chain management across disparate sectors. Furthermore, the mandatory transition to full SEBI corporate governance compliance is a critical milestone that the company must successfully navigate in FY 2026-27.
What to track next
Growth trends remain difficult to quantify due to the lack of historical comparable data. Future investor focus will likely shift toward consistent performance in the healthcare and renewable energy verticals and the company's ability to maintain its post-merger profitability margins.